A Look at Jazz Pharmaceuticals's Valuation After Landmark HERIZON-GEA-01 Ziihera Trial Results
Simply Wall St 22/11 16:23
B of A Securities Downgrades Schneider National to Underperform, Maintains Price Target to $23
Schneider National, Inc. Class B SNDR | 0.00 |
